M6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum

– Discussion to include progress and innovations in next-generation therapies for the treatment of lysosomal storage disorders – ST. LOUIS, Mo., – June 25, 2021 – M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced that Pawel Krysiak, M6PT’s president and …

Continue reading